Overview

Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants

Status:
Completed
Trial end date:
2018-01-30
Target enrollment:
Participant gender:
Summary
This study will be conducted to evaluate the relative bioavailability, pharmacokinetics, safety, and tolerability of AVP-923 (dextromethorphan hydrobromide [DM] and quinidine sulfate [Q] capsules) when the contents of a capsule are administered in applesauce or via a nasogastric feeding tube, compared with administration of a capsule in healthy, fasting, adult participants.
Phase:
Phase 1
Details
Lead Sponsor:
Avanir Pharmaceuticals
Treatments:
Dextromethorphan
Quinidine